Pachyonychia congenita cornered: Report on the 11th annual international pachyonychia congenita consortium meeting

British Journal of Dermatology

Volumn 171, Issue 5, 2014, Pages 974-977

  O'Toole, E A ^a   Kaspar, R L ^b   Sprecher, E ^c   Schwartz, M E ^d   Rittie L ^e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b TransDerm Inc   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d Pachyonychia Congenita Project   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; RAPAMYCIN; SHORT HAIRPIN RNA; DERMATOLOGICAL AGENT;

ARTICLE; CONGENITAL PACHYONYCHIA; CONSENSUS DEVELOPMENT; FUNDING; GENE DELETION; HUMAN; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PATHOGENESIS; SKIN BIOPSY; UNITED STATES; GENETICS; INTRADERMAL DRUG ADMINISTRATION; MUTATION; OFF LABEL DRUG USE; ORGANIZATION; PACHYONYCHIA CONGENITA;

ADMINISTRATION, CUTANEOUS; CAPSAICIN; CONGRESSES AS TOPIC; DERMATOLOGIC AGENTS; HUMANS; MUTATION; OFF-LABEL USE; PACHYONYCHIA CONGENITA; SIROLIMUS;

EID: 84911369491     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13341     Document Type: Article

References (19)

1. Wilson NJ, O'Toole E, Milstone LM, et al,. The molecular genetic analysis of the expanding pachyonychia congenita case collection. Br J Dermatol 2014; 171: 343-55.
2. Eliason MJ, Leachman SA, Feng BJ, et al,. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol 2012; 67: 680-6.
3. Schwartz ME, Hansen CD, Paller AS, et al,. Pachyonychia congenita overview. Dermatologist 2014; 22: 36-8.
4. McLean WH, Hansen CD, Eliason MJ, Smith FJ,. The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol 2011; 131: 1015-17.
5. Leachman SA, Hickerson RP, Schwartz ME, et al,. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010; 18: 442-6.
6. Hickerson RP, Leake D, Pho LN, et al,. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci 2009; 56: 82-8.
7. Goldberg I, Fruchter D, Meilick A, et al,. Best treatment practices for pachyonychia congenita. J Eur Acad Dermatol Venereol 2014; 28: 279-85.
8. Chen J, Jaeger K, Den Z, et al,. Mice expressing a mutant Krt75 (K6hf) allele develop hair and nail defects resembling pachyonychia congenita. J Invest Dermatol 2008; 128: 270-9.
9. Rice RH, Bradshaw KM, Durbin-Johnson BP, et al,. Distinguishing ichthyoses by protein profiling. PLoS One 2013; 8: e75355.
10. Rittié L, Sachs DL, Orringer JS, et al,. Eccrine sweat glands are major contributors to reepithelialization of human wounds. Am J Pathol 2013; 182: 163-71.
11. Goldberg I, Sprecher E, Schwartz ME, Gaitini D,. Comparative study of high-resolution multifrequency ultrasound of the plantar skin in patients with various types of hereditary palmoplantar keratoderma. Dermatology 2013; 226: 365-70.
12. Goldberg YP, Cohen CJ, Namdari R, et al,. Letter to the editor. Pain 2014; 155: 837-8.
13. v1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain 2012; 153: 80-5.
14. Samuelov L, Sarig O, Harmon RM, et al,. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013; 45: 1244-8.
15. Lin Z, Chen Q, Lee M, et al,. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. Am J Hum Genet 2012; 90: 558-64.
16. Shen J, van den Bogaard EH, Kouwenhoven EN, et al,. APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. Proc Natl Acad Sci U S A 2013; 110: 2157-62.
17. Haber RM, Drummond D,. Pachyonychia congenita with laryngeal obstruction. Pediatr Dermatol 2011; 28: 429-32.
18. Pergolizzi J, Ahlbeck K, Aldington D, et al,. The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment. Curr Med Res Opin 2013; 29: 1127-35.
19. Anand P, Bley K,. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107: 490-502.